Molecular markers for cervical cancer screening

References

• Sung H, Ferlay J, Siegel R. L., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021(71):209–249.
   Google Scholar
• Couvreur K, Naert E, De Jaeghere E, et al. Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates. BMC Cancer. 2018 Nov 12;18(1):1101.
   PubMed Web of Science ®Google Scholar
• Chrysostomou AC, Kostrikis LG. Methodologies of primary HPV testing currently applied for cervical cancer screening. Life (Basel). 2020 Nov 19;10(11):290.
   PubMed Web of Science ®Google Scholar
• Screening for cervical cancer invitation: RIVM: Rijksinstituut voor Volksgezondheid en Milieu. 2019. [cited 21 Jun 2021]. Available from: https://www.rivm.nl
   Google Scholar
• [cited 2021 Jun 21]. Available from: https://www.rivm.nl/documenten/uitvoeringskader-bevolkingsonderzoek-baarmoederhalskanker
   Google Scholar
• Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020 Sep;70(5):321–346.
   PubMed Web of Science ®Google Scholar
• Steenbergen RD, Snijders PJ, Heideman DA, et al. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014 Jun;14(6):395–405.
   PubMed Web of Science ®Google Scholar
• Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007 Jan;7(1):11–22.
   PubMed Web of Science ®Google Scholar
• Komdeur FL, Prins TM, van de Wall S, et al. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology. 2017;6(9):e1338230.
   PubMed Web of Science ®Google Scholar
• Chen CC, Huang LW, Bai CH, et al. Predictive value of p16/Ki-67 immunocytochemistry for triage of women with abnormal Papanicolaou test in cervical cancer screening: a systematic review and meta-analysis. Ann Saudi Med. 2016 Jul-Aug;36(4):245–251.
   PubMed Web of Science ®Google Scholar
• Drolet M, Benard E, Perez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Aug 10;394(10197):497–509.
   PubMed Web of Science ®Google Scholar
• Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012 Nov 15;131(10):2349–2359.
   PubMed Web of Science ®Google Scholar
• Chabeda A, Yanez RJR, Lamprecht R, et al. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018 Jun;5:46–58.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang D, Gu Y, et al. Crystal structures of two immune complexes identify determinants for viral infectivity and type-specific neutralization of human papillomavirus. mBio. 2017;8(5):e00787–17.
   Google Scholar
• Matthijsse SM, Naber SK, Hontelez JAC, et al. The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: a mathematical modeling study. PLoS One. 2018;13(9):e0202924.
   PubMed Web of Science ®Google Scholar
• Diaz M, de Sanjose S, Bosch FX, et al. Present challenges in cervical cancer prevention: answers from cost-effectiveness analyses. Rep Pract Oncol Radiother. 2018 Nov-Dec;23(6):484–494.
   PubMedGoogle Scholar
• Santhanes D, Wong CP, Yap YY, et al. Factors involved in human papillomavirus (HPV) vaccine hesitancy among women in the South-East Asian Region (SEAR) and Western Pacific Region (WPR): a scoping review. Hum Vaccin Immunother. 2018 Jan 2;14(1):124–133.
   PubMed Web of Science ®Google Scholar
• Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020 Feb 22;395(10224):575–590.
   PubMed Web of Science ®Google Scholar
• Rousseau S, Gaillot-de Saintignon J, Barret AS. Challenges in the implementation of HPV vaccination for cancer prevention. Rev Prat. 2019 May;69(5):529–534.
   PubMedGoogle Scholar
• Papanicolaou GN. A new procedure for staining vaginal smears. Science. 1942 Apr 24;95(2469):438–439.
   PubMedGoogle Scholar
• Nance KV. Evolution of Pap testing at a community hospital: a ten year experience. Diagn Cytopathol. 2007 Mar;35(3):148–153.
   PubMed Web of Science ®Google Scholar
• Naeem RC, Goldstein DY, Einstein MH, et al. SurePath specimens versus thinprep specimen types on the COBAS 4800 platform: high-risk HPV status and cytology correlation in an ethnically diverse bronx population. Lab Med. 2017 Aug 1;48(3):207–213.
   PubMed Web of Science ®Google Scholar
• Luttmer R, De Strooper LM, Berkhof J, et al. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). Int J Cancer. 2016 Feb 15;138(4):992–1002.
   PubMed Web of Science ®Google Scholar
• Luttmer R, Dijkstra MG, Snijders PJ, et al. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol. 2016 Aug;29(8):870–878.
   PubMed Web of Science ®Google Scholar
• Sargent A, Fletcher S, Bray K, et al. Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening. BMJ Open. 2019 Apr 29;9(4):e025388.
   PubMed Web of Science ®Google Scholar
• Hawkes D, Keung MHT, Huang Y, et al. Self-Collection for cervical screening programs: from research to reality. Cancers (Basel). 2020 Apr 24;12(4):1053.
   PubMed Web of Science ®Google Scholar
• Xue P, Ng MTA, Qiao Y. The challenges of colposcopy for cervical cancer screening in LMICs and solutions by artificial intelligence. BMC Med. 2020 Jun 3;18(1):169.
   PubMed Web of Science ®Google Scholar
• Chitra B, Kumar SS. Recent advancement in cervical cancer diagnosis for automated screening: a detailed review. J Ambient Intell Humaniz Comput 2021. DOI:https://doi.org/10.1007/s12652-021-02899-2.
   Google Scholar
• Poljak M, Ostrbenk Valencak A, Gimpelj Domjanic G, et al. Commercially available molecular tests for human papillomaviruses: a global overview. Clin Microbiol Infect. 2020 Sep;26(9):1144–1150.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Snijders PJ, Meijer CJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015 Sep;21(9):817–826.
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Arbyn M, Bergeron C, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020 Aug;123(4):510–517.
   PubMed Web of Science ®Google Scholar
• Zhao FH, Jeronimo J, Qiao YL, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila). 2013 Sep;6(9):938–948.
   PubMed Web of Science ®Google Scholar
• Loonen AJM, Huijsmans CJJ, WRR G-G, et al. Performance analysis of high-throughput HPV testing on three automated workflows. APMIS. 2020 Aug;128(8):497–505.
   PubMed Web of Science ®Google Scholar
• Torres M, Fraile L, Echevarria J, et al. Human Papillomavirus (HPV) Genotyping: automation and application in routine laboratory testing. Open Virol J. 2012;6(1):144–150.
   PubMedGoogle Scholar
• Fu XL, Schiffman M, Ke Y, et al. Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18. Int J Cancer. 2017 Apr 15;140(8):1747–1756.
   PubMed Web of Science ®Google Scholar
• Floore A, Hesselink A, Ostrbenk A, et al. Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: results from an international study. J Clin Lab Anal. 2019 May;33(4):e22854.
   PubMed Web of Science ®Google Scholar
• Dippmann C, Schmitz M, Wunsch K, et al. Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays. Clin Epigenetics. 2020 Nov 11;12(1):171.
   PubMed Web of Science ®Google Scholar
• Kurdyukov S, Bullock M, Methylation analysis: choosing the right method. Biology (Basel). 2016 Jan 6;5(1):3.
   PubMedGoogle Scholar
• Rauluseviciute I, Drablos F, Rye MB. DNA methylation data by sequencing: experimental approaches and recommendations for tools and pipelines for data analysis. Clin Epigenetics. 2019 Dec 12;11(1):193.
   PubMed Web of Science ®Google Scholar
• Pouliquen DL, Boissard A, Coqueret O, et al. Biomarkers of tumor invasiveness in proteomics (Review). Int J Oncol. 2020 Aug;57(2):409–432.
   PubMed Web of Science ®Google Scholar
• Vasiljevic N, Carter PD, Reuter C, et al. Role of quantitative p16 INK4A mRNA assay and digital reading of p16 INK4A immunostained sections in diagnosis of cervical intraepithelial neoplasia. Int J Cancer. 2017 Aug 15;141(4):829–836.
   PubMed Web of Science ®Google Scholar
• Han C, Zhao F, Wan C, et al. Associations between the expression of SCCA, MTA1, P16, Ki-67 and the infection of high-risk HPV in cervical lesions. Oncol Lett. 2020 Jul;20(1):884–892.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-Positive women. J Natl Cancer Inst. 2015 Dec;107(12):djv257.
   Google Scholar
• Wright TC Jr., Behrens CM, Ranger-Moore J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017 Jan;144(1):51–56.
   PubMed Web of Science ®Google Scholar
• Dixon EP, King LM, Nelson R, et al. Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx C assay: an immunoassay which detects aberrant S-phase induction in cervical tissue. J Immunol Methods. 2017 Mar;442:35–41.
   PubMed Web of Science ®Google Scholar
• Van Gool A, Corrales F, Colovic M, et al. Analytical techniques for multiplex analysis of protein biomarkers. Expert Rev Proteomics. 2020 Apr;17(4):257–273.
   PubMed Web of Science ®Google Scholar
• Ye S, Sun X, Kang B, et al. The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study. BMC Cancer. 2020 Feb 21;20(1):138.
   PubMed Web of Science ®Google Scholar
• Rivnak AJ, Rissin DM, Kan CW, et al. A fully-automated, six-plex single molecule immunoassay for measuring cytokines in blood. J Immunol Methods. 2015 Sep;424:20–27.
   PubMed Web of Science ®Google Scholar
• Kundrod KA, Smith CA, Hunt B, et al. Advances in technologies for cervical cancer detection in low-resource settings. Expert Rev Mol Diagn. 2019 Aug;19(8):695–714.
   PubMed Web of Science ®Google Scholar
• Krings A, Duckelmann AM, Moser L, et al. Performance of OncoE6 cervical test with collection methods enabling self-sampling. BMC Womens Health. 2018 May 21;18(1):68.
   PubMed Web of Science ®Google Scholar
• Ndizeye Z, Menon S, Van Geertruyden JP, et al. Performance of OncoE6(TM) Cervical Test in detecting cervical precancer lesions in HIV-positive women attending an HIV clinic in Bujumbura, Burundi: a cross-sectional study. BMJ Open. 2019 Sep 6;9(9):e029088.
   PubMed Web of Science ®Google Scholar
• Ferrera A, Valladares W, Cabrera Y, et al. Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer. Int J Cancer. 2019 Oct 15;145(8):2042–2050.
   PubMed Web of Science ®Google Scholar
• Kelly H, Mayaud P, Segondy M, et al. A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening. Sex Transm Infect. 2017 Dec;93(S4):S36–S45.
   PubMed Web of Science ®Google Scholar
• Rezhake R, Hu SY, Zhao S, et al. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women. Int J Cancer. 2019 Jan 1;144(1):34–42.
   PubMed Web of Science ®Google Scholar
• Panikar, S. S.; Banu, N.; Haramati, J.; et al. Anti-fouling SERS-based immunosensor for point-of-care detection of the B7-H6 tumor biomarker in cervical cancer patient serum. Anal Chim Acta 2020;1138:110–122.
   Google Scholar
• Ren W, Mohammed SI, Wereley S, et al. Magnetic focus lateral flow sensor for detection of cervical cancer biomarkers. Anal Chem. 2019 Feb 19;91(4):2876–2884.
   PubMed Web of Science ®Google Scholar
• Villa LL, Denny L. CHAPTER 7 Methods for detection of HPV infection and its clinical utility. Int J Gynaecol Obstet. 2006 Nov;94(Suppl 1):S71–S80.
   PubMed Web of Science ®Google Scholar
• Keeratichamroen S, Subhasitanont P, Chokchaichamnankit D, et al. Identification of potential cervical cancer serum biomarkers in Thai patients. Oncol Lett. 2020 Jun;19(6):3815–3826.
   PubMed Web of Science ®Google Scholar
• Hellman K, Alaiya AA, Becker S, et al. Differential tissue-specific protein markers of vaginal carcinoma. Br J Cancer. 2009 Apr 21;100(8):1303–1314.
   PubMed Web of Science ®Google Scholar
• Liu C, Pan C, Shen J, et al. Discrimination analysis of mass spectrometry proteomics for cervical cancer detection. Med Oncol. 2011 Dec;28(Suppl 1):S553–9.
   PubMed Web of Science ®Google Scholar
• Kriegsmann J, Kriegsmann M, Kriegsmann K, et al. MALDI imaging for proteomic painting of heterogeneous tissue structures. Proteomics Clin Appl. 2019 Jan;13(1):e1800045.
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Cadron I, Daemen A, et al. Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS. Proteome Sci. 2012 Jun 13;10(1):41.
   PubMed Web of Science ®Google Scholar
• Longuespee R, Ly A, Casadonte R, et al. Identification of MALDI imaging proteolytic peptides using LC-MS/MS-Based biomarker discovery data: a proof of concept. Proteomics Clin Appl. 2019 Jan;13(1):e1800158.
   PubMed Web of Science ®Google Scholar
• Han J, Permentier H, Bischoff R, et al. Imaging of protein distribution in tissues using mass spectrometry: an interdisciplinary challenge TrAC - Trends in Analytical Chemistry. 2019;112:13–28.
   Google Scholar
• Tzafetas M, Mitra A, Paraskevaidi M, et al. The intelligent knife (iKnife) and its intraoperative diagnostic advantage for the treatment of cervical disease. Proc Natl Acad Sci U S A. 2020 Mar 31 117(13):7338–7346.
   PubMed Web of Science ®Google Scholar
• Paraskevaidi M, Cameron SJS, Whelan E, et al. Laser-assisted rapid evaporative ionisation mass spectrometry (LA-REIMS) as a metabolomics platform in cervical cancer screening. EBioMedicine. 2020 Oct;60:103017.
   PubMed Web of Science ®Google Scholar
• Shu W, Wang Y, Liu C, et al. Construction of a plasmonic chip for metabolic analysis in cervical cancer screening and evaluation small methods. Small Methods. 2020;4:4.
   Google Scholar
• Zhou W, Huang C, Zou X, et al. Exhaled breath online measurement for cervical cancer patients and healthy subjects by proton transfer reaction mass spectrometry. Anal Bioanal Chem. 2017 Sep;409(23):5603–5612.
   PubMed Web of Science ®Google Scholar
• Khan I, Nam M, Kwon M, et al. LC/MS-Based polar metabolite profiling identified unique biomarker signatures for cervical cancer and cervical intraepithelial neoplasia using global and targeted metabolomics. Cancers (Basel). 2019 Apr 10;11(4):511.
   Web of Science ®Google Scholar
• Govorukhina NI, Reijmers TH, Nyangoma SO, et al. Analysis of human serum by liquid chromatography-mass spectrometry: improved sample preparation and data analysis. J Chromatogr A. 2006 Jul 7;1120(1–2):142–150.
   PubMed Web of Science ®Google Scholar
• Hao Y, Ye M, Chen X, et al. Discovery and validation of FBLN1 and ANT3 as potential biomarkers for early detection of cervical cancer. Cancer Cell Int. 2021 Feb 18;21(1):125.
   PubMed Web of Science ®Google Scholar
• Kontostathi G, Zoidakis J, Anagnou NP, et al. Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. Expert Rev Proteomics. 2016 Aug;13(8):731–745.
   PubMed Web of Science ®Google Scholar
• Guo X, Hao Y, Kamilijiang M, et al. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and ingenuity pathway analysis. Tumour Biol. 2015 Mar;36(3):1711–1720.
   PubMed Web of Science ®Google Scholar
• Bae SM, Lee CH, Cho YL, et al. Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol. 2005 Oct;99(1):26–35.
   PubMed Web of Science ®Google Scholar
• Govorukhina N, Horvatovich P, Bischoff R. Label-free proteomics of serum. Methods Mol Biol. 2008;484:67–77.
   PubMedGoogle Scholar
• Chokchaichamnankit D, Watcharatanyatip K, Subhasitanont P, et al. Urinary biomarkers for the diagnosis of cervical cancer by quantitative label-free mass spectrometry analysis. Oncol Lett. 2019 Jun;17(6):5453–5468.
   PubMed Web of Science ®Google Scholar
• Boichenko AP, Govorukhina N, Klip HG, et al. A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer. J Proteome Res. 2014 Nov 7;13(11):4995–5007.
   PubMed Web of Science ®Google Scholar
• Güzel C, Govorukhina NI, Wisman GBA, et al. Proteomic alterations in early stage cervical cancer. Oncotarget. 2018;9(26):18128–18147.
   PubMedGoogle Scholar
• Filippova M, Filippov V, Williams VM, et al. Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. Biomed Res Int. 2014;2014:574659.
   PubMed Web of Science ®Google Scholar
• Guzel C, Govorukhina NI, Stingl C, et al. Comparison of targeted mass spectrometry techniques with an immunoassay: a case study for HSP90alpha. Proteomics Clin Appl. 2018;12:1700107.
   Web of Science ®Google Scholar
• Stevens KG, Pukala TL. Conjugating immunoassays to mass spectrometry: solutions to contemporary challenges in clinical diagnostics. Trends Analyt Chem. 2020 Nov;132:116064.
   PubMed Web of Science ®Google Scholar
• Pratt MS, van Faassen M, Remmelts N, et al. An antibody-free LC-MS/MS method for the quantification of intact insulin-like growth factors 1 and 2 in human plasma. Anal Bioanal Chem. 2021 Mar;413(8):2035–2044.
   PubMed Web of Science ®Google Scholar
• Klont F, Pouwels SD, Hermans J, et al. A fully validated liquid chromatography-mass spectrometry method for the quantification of the soluble receptor of advanced glycation end-products (sRAGE) in serum using immunopurification in a 96-well plate format. Talanta. 2018 May 15;182:414–421.
   PubMed Web of Science ®Google Scholar
• Klont F, Hadderingh M, Horvatovich P, et al. Affimers as an alternative to antibodies in an affinity LC-MS assay for quantification of the Soluble Receptor of Advanced Glycation End-Products (sRAGE) in human serum. J Proteome Res. 2018 Aug 3;17(8):2892–2899.
   PubMed Web of Science ®Google Scholar
• Szalmas A, Konya J. Epigenetic alterations in cervical carcinogenesis. Semin Cancer Biol. 2009 Jun;19(3):144–152.
   PubMed Web of Science ®Google Scholar
• Kremer WW, Steenbergen R, Heideman D, et al. The use of host cell DNA methylation analysis in the detection and management of women with advanced cervical intraepithelial neoplasia: a review. BJOG. 2021 Feb;128(3):504–514.
   PubMed Web of Science ®Google Scholar
• Laengsri V, Kerdpin U, Plabplueng C, et al. Cervical Cancer Markers: epigenetics and microRNAs. Lab Med. 2018 Mar 21;49(2):97–111.
   PubMed Web of Science ®Google Scholar
• Bhat S, Kabekkodu SP, Noronha A, et al. Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. Biochimie. 2016 Feb;121:298–311.
   PubMed Web of Science ®Google Scholar
• Lorincz AT. Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Rev Mol Diagn. 2014 Apr;14(3):293–305.
   PubMed Web of Science ®Google Scholar
• Verma M. The role of epigenomics in the study of cancer biomarkers and in the development of diagnostic tools. Adv Exp Med Biol. 2015;867:59–80.
   PubMed Web of Science ®Google Scholar
• Fang J, Zhang H, Jin S. Epigenetics and cervical cancer: from pathogenesis to therapy. Tumour Biol. 2014 Jun;35(6):5083–5093.
   PubMedGoogle Scholar
• Wilting SM, Steenbergen RDM. Molecular events leading to HPV-induced high grade neoplasia. Papillomavirus Res. 2016 Dec;2:85–88.
   PubMed Web of Science ®Google Scholar
• Boers A, Wang R, van Leeuwen RW, et al. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics. 2016;8(1):29.
   PubMed Web of Science ®Google Scholar
• De Strooper LMA, Verhoef VMJ, Berkhof J, et al. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol. 2016 May;141(2):341–347.
   PubMed Web of Science ®Google Scholar
• Luttmer R, De Strooper LM, Dijkstra MG, et al. FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br J Cancer. 2016 Aug 23;115(5):579–587.
   PubMed Web of Science ®Google Scholar
• Lorincz AT, Brentnall AR, Scibior-Bentkowska D, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016 Jun 1;138(11):2745–2751.
   PubMed Web of Science ®Google Scholar
• Dick S, Verhoef L, De Strooper LM, et al. Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics. 2020 Sep;12(18):1569–1578.
   PubMed Web of Science ®Google Scholar
• Babion I, De Strooper LMA, Luttmer R, et al. Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease. Epigenetics. 2019 Jun;14(6):558–567.
   PubMed Web of Science ®Google Scholar
• Schmitz M, Eichelkraut K, Schmidt D, et al. Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages. BMC Cancer. 2018 Dec 3;18(1):1197.
   PubMed Web of Science ®Google Scholar
• Lorincz AT. Virtues and weaknesses of DNA methylation as a test for cervical cancer prevention. Acta Cytol. 2016;60(6):501–512.
   PubMed Web of Science ®Google Scholar
• Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013 Oct 16;105(20):1550–1557.
   PubMedGoogle Scholar
• Sarwath H, Bansal D, Husain NE, et al. Introduction of p16(INK4a) as a surrogate biomarker for HPV in women with invasive cervical cancer in Sudan. Infect Agent Cancer. 2017;12(1):50.
   PubMed Web of Science ®Google Scholar
• von Knebel Doeberitz M, Reuschenbach M, Schmidt D, et al. Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics. 2012 Apr;9(2):149–163.
   PubMed Web of Science ®Google Scholar
• Stevenson A, Kavanagh K, Pan J, et al. Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples. J Clin Virol. 2018 Nov;108:19–25.
   PubMed Web of Science ®Google Scholar
• Amaro Filho SM, Nuovo GJ, Cunha CB, et al. Correlation of MCM2 detection with stage and virology of cervical cancer. Int J Biol Markers. 2014 Dec 9;29(4):e363–71.
   PubMed Web of Science ®Google Scholar
• Valverde LF, de Freitas RD, Pereira TA, et al. MCM3: a novel proliferation marker in oral squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):120–125.
   PubMedGoogle Scholar
• Aporowicz M, Czopnik P, Kubicka E, et al. Minichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67 as proliferative markers in adrenocortical tumors. Anticancer Res. 2019 Mar;39(3):1151–1159.
   PubMed Web of Science ®Google Scholar
• Branca M, Giorgi C, Ciotti M, et al. Over-expression of topoisomerase IIalpha is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment. Int J Gynecol Pathol. 2006 Oct;25(4):383–392.
   PubMed Web of Science ®Google Scholar
• Jenson EG, Baker M, Paydarfar JA, et al. MCM2/TOP2A (ProExC) immunohistochemistry as a predictive marker in head and neck mucosal biopsies. Pathol Res Pract. 2014 Jun;210(6):346–350.
   PubMed Web of Science ®Google Scholar
• Ebisch RM, van der Horst J, Hermsen M, et al. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. Mod Pathol. 2017 Jul;30(7):1021–1031.
   PubMed Web of Science ®Google Scholar
• Kelly D, Kincaid E, Fansler Z, et al. Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx C). Cancer. 2006 Dec 25;108(6):494–500.
   PubMed Web of Science ®Google Scholar
• Moiseeva TN, Bakkenist CJ. Regulation of the initiation of DNA replication in human cells. DNA Repair (Amst). 2018 Dec;72:99–106.
   PubMed Web of Science ®Google Scholar
• Bialik S, Berissi H, Kimchi A. A high throughput proteomics screen identifies novel substrates of death-associated protein kinase. Mol Cell Proteomics. 2008 Jun;7(6):1089–1098.
   PubMed Web of Science ®Google Scholar
• Fei L, Xu H. Role of MCM2-7 protein phosphorylation in human cancer cells. Cell Biosci. 2018;8(1):43.
   PubMed Web of Science ®Google Scholar
• Yang P, Chen N, Yang D, et al. The ratio of serum Angiopoietin-1 to Angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker. PeerJ. 2017;5:e3387.
   PubMed Web of Science ®Google Scholar
• Li X, Tian R, Gao H, et al. Identification of significant gene signatures and prognostic biomarkers for patients with cervical cancer by integrated bioinformatic methods. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818767455.
   Web of Science ®Google Scholar
• Friese K, Kost B, Vattai A, et al. The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer. J Cancer Res Clin Oncol. 2018 Jan;144(1):13–19.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xiong X, Wang Y, et al. Proteomic screening for serum biomarkers for cervical cancer and their clinical significance. Med Sci Monit. 2019 Jan;9(25):288–297.
   Web of Science ®Google Scholar
• Guo X, Abliz G, Reyimu H, et al. The association of a distinct plasma proteomic profile with the cervical high-grade squamous intraepithelial lesion of Uyghur women: a 2D liquid-phase chromatography/mass spectrometry study. Biomarkers. 2012 Jun;17(4):352–361.
   PubMed Web of Science ®Google Scholar
• Curty G, de Carvalho PS, Soares MA. The role of the cervicovaginal microbiome on the genesis and as a biomarker of premalignant cervical intraepithelial neoplasia and invasive cervical cancer. Int J Mol Sci. 2019 Dec 28;21(1)222.
   PubMed Web of Science ®Google Scholar
• Castanheira CP, Sallas ML, Nunes RAL, et al. Microbiome and cervical cancer. Pathobiology. 2021;88(2):187–197.
   PubMed Web of Science ®Google Scholar
• Champer M, Wong AM, Champer J, et al. The role of the vaginal microbiome in gynaecological cancer. BJOG. 2018 Feb;125(3):309–315.
   PubMed Web of Science ®Google Scholar
• Starodubtseva NL, Brzhozovskiy AG, Bugrova AE, et al. Label-free cervicovaginal fluid proteome profiling reflects the cervix neoplastic transformation. J Mass Spectrom. 2019 Aug;54(8):693–703.
   PubMed Web of Science ®Google Scholar
• Liu C, Pan C, Shen J, et al. Discrimination analysis of mass spectrometry proteomics for cervical cancer detection. Med Oncol. 2011 Dec;28(Suppl 1):S553–9.
   PubMed Web of Science ®Google Scholar
• Panicker G, Ye Y, Wang D, et al. Characterization of the human cervical mucous proteome. Clin Proteomics. 2010 6;Jun(1–2):18–28.
   Google Scholar
• Van Ostade X, Dom M, Tjalma W, et al. Candidate biomarkers in the cervical vaginal fluid for the (self-)diagnosis of cervical precancer. Arch Gynecol Obstet. 2018 Feb;297(2):295–311.
   PubMed Web of Science ®Google Scholar
• Gutierrez AL, Lindberg JH, Shevchenko G, et al. Identification of candidate protein biomarkers for CIN2+ lesions from self-sampled, dried cervico-vaginal fluid using LC-MS/MS. Cancers (Basel). 2021 May 25;13(11):2592.
   Web of Science ®Google Scholar
• Cardoso MFS, Castelletti CHM, Lima-Filho JL, et al. Putative biomarkers for cervical cancer: SNVs, methylation and expression profiles. Mutat Res. 2017 Jul;773:161–173.
   Web of Science ®Google Scholar
• van Baars R, Griffin H, Wu Z, et al. Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPVE4 with P16INK4a. Am J Surg Pathol. 2015 Nov;39(11):1518–1528.
   PubMed Web of Science ®Google Scholar
• Griffin H, Soneji Y, Van Baars R, et al. Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM. Mod Pathol. 2015 Jul;28(7):977–993.
   PubMed Web of Science ®Google Scholar
• de Kok I, Korfage IJ, van den Hout WB, et al. Quality of life assumptions determine which cervical cancer screening strategies are cost-effective. Int J Cancer. 2018 Jun 1;142(11):2383–2393.
   PubMed Web of Science ®Google Scholar
• Jansen E, Naber SK, Aitken CA, et al. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study. BJOG. 2021 Feb;128(3):573–582.
   PubMed Web of Science ®Google Scholar
• Kaljouw S, Jansen EEL, Aitken CA, et al. Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: a modelling study. Gynecol Oncol. 2021 Mar;160(3):713–720.
   PubMed Web of Science ®Google Scholar
• Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812–3815.
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002 May 2;2(5):342–350.
   PubMed Web of Science ®Google Scholar